Citius Oncology has entered a senior secured credit facility with Avenue Capital Group for up to $25 million, including an initial $10 million tranche, to support the commercialization of its FDA-approved cancer drug LYMPHIR. Concurrently, the company raised approximately $11.5 million through the exercise of warrants by a healthcare-focused investor. These financings provide Citius Oncology with enhanced financial flexibility to expand sales, market access, and manufacturing efforts for LYMPHIR, targeting relapsed or refractory cutaneous T-cell lymphoma. The funds will also support working capital and general corporate purposes as the company scales its commercial infrastructure.
The Rosen Law Firm is investigating a class action lawsuit on behalf of Barclays PLC shareholders following reports that Barclays had significant exposure to a collapsed UK mortgage lender, Market Financial Solutions Ltd (MFS). The news caused Barcla...
WEMIX, a South Korean blockchain gaming platform, is investigating a potential security breach involving the ownership of its USDC-backed stablecoin contract, WEMIX$. This comes months after a major hack in February 2025 that drained $6.1 million wor...
XRP remains range-bound near $1.10 amid slowing spot ETF inflows, which are seen as key to breaking its two-month trading range. Despite positive developments like Mastercard's AI payment integration, Ripple Mint platform launch, and EU regulatory ap...
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
This week, U.S. markets focus on the Federal Reserve's July meeting, key inflation data like Core PCE, and second-quarter GDP figures, alongside major tech earnings from Microsoft, Meta, Apple, and Amazon. Rising oil prices and geopolitical tensions ...
